Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study

J. Romme Christensen; R. Ratzer; L. Bornsen; E. Garde; Mark Lyksborg; H. R. Siebner; T. B. Dyrby; P. S. Sørensen; F. Sellebjerg

doi:10.1177/1352458512461105

Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study

J. Romme Christensen, R. Ratzer, L. Bornsen, E. Garde, Mark Lyksborg, H. R. Siebner, T. B. Dyrby, P. S. Sørensen, F. Sellebjerg

Unknown

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Multiple Sclerosis
Volume	18
Issue number	4 supplement
Pages (from-to)	514-515
ISSN	1352-4585
DOIs	https://doi.org/10.1177/1352458512461105
Publication status	Published - 2012
Externally published	Yes
Event	28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis - Lyon, France Duration: 10 Oct 2012 → 13 Oct 2012 http://www.ectrims-congress.eu/2012.html

Conference

Conference	28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Country/Territory	France
City	Lyon
Period	10/10/2012 → 13/10/2012
Internet address	http://www.ectrims-congress.eu/2012.html

Access to Document

10.1177/1352458512461105

OpenUrl availability

Full text

Cite this

Christensen, J. R., Ratzer, R., Bornsen, L., Garde, E., Lyksborg, M., Siebner, H. R., Dyrby, T. B., Sørensen, P. S., & Sellebjerg, F. (2012). Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study. Multiple Sclerosis, 18(4 supplement), 514-515. https://doi.org/10.1177/1352458512461105

@article{b48e87e05ac64d8e9b65807e09238806,

title = "Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study",

author = "Christensen, {J. Romme} and R. Ratzer and L. Bornsen and E. Garde and Mark Lyksborg and Siebner, {H. R.} and Dyrby, {T. B.} and S{\o}rensen, {P. S.} and F. Sellebjerg",

year = "2012",

doi = "10.1177/1352458512461105",

language = "English",

volume = "18",

pages = "514--515",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "4 supplement",

note = "28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ; Conference date: 10-10-2012 Through 13-10-2012",

url = "http://www.ectrims-congress.eu/2012.html",

}

Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study. / Christensen, J. Romme; Ratzer, R.; Bornsen, L. et al.

In: Multiple Sclerosis, Vol. 18, No. 4 supplement, 2012, p. 514-515.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study

AU - Christensen, J. Romme

AU - Ratzer, R.

AU - Bornsen, L.

AU - Garde, E.

AU - Lyksborg, Mark

AU - Siebner, H. R.

AU - Dyrby, T. B.

AU - Sørensen, P. S.

AU - Sellebjerg, F.

PY - 2012

Y1 - 2012

U2 - 10.1177/1352458512461105

DO - 10.1177/1352458512461105

M3 - Conference abstract in journal

VL - 18

SP - 514

EP - 515

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 4 supplement

T2 - 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Y2 - 10 October 2012 through 13 October 2012

ER -